文献速递核素与放射性配体治疗

5-甲基四氢叶酸类放射性偶联物的临床前评估:叶酸受体靶向放射性核素治疗新视角

Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives for folate receptor-targeted radionuclide therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-10-15

本研究在FR阳性KB肿瘤细胞及荷瘤小鼠中评估了以5-MTHF为靶向剂、可结合白蛋白的新型放射性偶联物[177Lu]Lu-6R-RedFol-1和[177Lu]Lu-6S-RedFol-1,并与[177Lu]Lu-OxFol-1比较。两种新偶联物体外性质相似但肿瘤摄取显著增加,其中[177Lu]Lu-6R-RedFol-1肾脏摄取与对照相似,肿瘤/肾脏AUC0→120h比值提高近4倍,等活度下疗效更优、中位生存期延长(49天 vs. 34天)。

要点

  • 5-MTHF基偶联物较叶酸基[177Lu]Lu-OxFol-1显著提高肿瘤摄取。
  • [177Lu]Lu-6R-RedFol-1肿瘤/肾脏AUC0→120h比值提高近4倍。
  • 等活度下[177Lu]Lu-6R-RedFol-1疗效优于[177Lu]Lu-OxFol-1,中位生存期49天 vs. 34天。

核心结论

  • 5-MTHF基放射性偶联物在FR靶向治疗中具有前景,[177Lu]Lu-6R-RedFol-1因高肿瘤/肾脏比值和更优疗效值得未来临床转化。

研究设计与样本

  • 临床前研究:在FR阳性KB肿瘤细胞中进行体外评估,在KB荷瘤小鼠中行生物分布研究并计算肿瘤与肾脏AUC0→120h。
  • 用KB荷瘤小鼠开展为期8周的治疗研究,比较[177Lu]Lu-6R-RedFol-1与[177Lu]Lu-OxFol-1。

主要发现

  • 两种新型偶联物体外性质与[177Lu]Lu-OxFol-1相似,但肿瘤摄取显著增加。
  • [177Lu]Lu-6S-RedFol-1的肾脏摄取也增加,而[177Lu]Lu-6R-RedFol-1的肾脏滞留与[177Lu]Lu-OxFol-1相似。
  • [177Lu]Lu-6R-RedFol-1的肿瘤/肾脏AUC0→120h比值较[177Lu]Lu-6S-RedFol-1和[177Lu]Lu-OxFol-1提高近4倍。
  • 等活度下[177Lu]Lu-6R-RedFol-1较[177Lu]Lu-OxFol-1肿瘤生长更慢,中位生存期延长(49天 vs. 34天)。

关键数值与推荐

  • 肿瘤/肾脏AUC0→120h比值:[177Lu]Lu-6R-RedFol-1较[177Lu]Lu-6S-RedFol-1和[177Lu]Lu-OxFol-1提高近4倍。
  • 中位生存期:[177Lu]Lu-6R-RedFol-1为49天,[177Lu]Lu-OxFol-1为34天。

临床怎么用

  • 提示5-MTHF基放射性偶联物可用于FR靶向放射性核素治疗,[177Lu]Lu-6R-RedFol-1因高肿瘤/肾脏比值和疗效优势具备临床转化潜力。

局限性

  • 研究仅为临床前体外与小鼠体内评估,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The folate receptor (FR) is frequently overexpressed in a variety of tumor types and, hence, an interesting target for radionuclide therapy. The aim of this study was to evaluate a new class of albumin-binding radioconjugates comprising 5-methyltetrahydrofolate (5-MTHF) as a targeting agent and to compare their properties with those of the previously established folic acid-based [177Lu]Lu-OxFol-1. METHODS: [177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-RedFol-1 were investigated in vitro using FR-positive KB tumor cells. Biodistribution studies were performed in KB tumor-bearing mice, and the areas under the curve (AUC0 → 120h) were determined for the uptake in tumors and kidneys. [177Lu]Lu-6R-RedFol-1 was compared with [177Lu]Lu-OxFol-1 in a therapy study over 8 weeks using KB tumor-bearing mice. RESULTS: Both radioconjugates demonstrated similar in vitro properties as [177Lu]Lu-OxFol-1; however, the tumor uptake of [177Lu]Lu-6R-RedFol-1 and [177Lu]Lu-6S-RedFol-1 was significantly increased in comparison with [177Lu]Lu-OxFol-1. In the case of [177Lu]Lu-6S-RedFol-1, also the kidney uptake was increased; however, renal retention of [177Lu]Lu-6R-RedFol-1 was similar to that of [177Lu]Lu-OxFol-1. This led to an almost 4-fold increased tumor-to-kidney AUC0 → 120h ratio of [177Lu]Lu-6R-RedFol-1 as compared with [177Lu]Lu-6S-RedFol-1 and [177Lu]Lu-OxFol-1. At equal activity, the therapeutic effect of [177Lu]Lu-6R-RedFol-1 was better than that of [177Lu]Lu-OxFol-1, reflected by a slower tumor growth and, consequently, an increased median survival time (49 days vs. 34 days). CONCLUSION: This study demonstrated the promising potential of 5-MTHF-based radioconjugates for FR-targeting. Application of [177Lu]Lu-6R-RedFol-1 resulted in unprecedentedly high tumor-to-kidney ratios and, as a consequence, a superior therapeutic effect as compared with [177Lu]Lu-OxFol-1. These findings, together with the absence of early side effects, make [177Lu]Lu-6R-RedFol-1 attractive in view of a future clinical translation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Guzik P, Benešová M, Ratz M, et al. Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives for folate receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 33063250. doi:10.1007/s00259-020-04980-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。